title: Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia.
abstract: OBJECTIVE
  To evaluate the outcomes of pregnancy in young women (<40 years old) with early endometrial cancer or atypical complex hyperplasia who were treated by conservative management followed by assisted reproductive technology (ART).
  
  
  METHODS
  Medical charts of 11 patients treated from January 1997 to October 2007 at Asan Medical Center were retrospectively reviewed. These patients had all been treated with progestin and serial dilatation and curettage as primary fertility-preserving therapies.
  
  
  RESULTS
  After pathological remission of disease, 10 patients tried to become pregnant by ART, 4 by in vitro fertilization and embryo transfer, and 6 by controlled ovarian hyperstimulation, with or without intrauterine insemination. Eight women had intrauterine pregnancies, and 6 patients had live births. Patients have been followed up for 9 to 51 months (mean, 21 months) after delivery, with no evidence of tumor recurrence.
  
  
  CONCLUSIONS
  Fertility-preserving therapy followed by ART can be a good option in well-selected patients with early endometrial cancer who want to become pregnant.
authors.affiliation: From the Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
authors.forename: Aera R
authors.initials: AR
authors.lastname: Han
authors.forename: Yong-Soon
authors.initials: YS
authors.lastname: Kwon
authors.forename: D Y
authors.initials: DY
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Kim
authors.forename: Y M
authors.initials: YM
authors.lastname: Kim
authors.forename: Y T
authors.initials: YT
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Nam
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004107:Dilatation and Curettage; D004714:Endometrial Hyperplasia / Q000628:therapy*; D016889:Endometrial Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000517:prevention & control; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D019290:Megestrol Acetate / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D027724:Reproductive Techniques, Assisted; D012189:Retrospective Studies
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate; D019290:Megestrol Acetate